Parkinson’s Disease – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Parkinson's Disease – Pipeline Review, H2 2020’, provides an overview of the Parkinson's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Parkinson's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease

– The report reviews pipeline therapeutics for Parkinson's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Parkinson's Disease therapeutics and enlists all their major and minor projects

– The report assesses Parkinson's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Parkinson's Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

1st Bio Therapeutics Inc

4D Pharma Plc

Abaxy Sprl

AbbVie Inc

Abfero Pharmaceuticals Inc

Abivax SA

ABL Bio Inc

AC Immune SA

Accure Therapeutics SL

Acelot Inc

Addex Therapeutics Ltd

Adicet Bio Inc

Affichem SA

AFFiRiS AG

AgoneX Biopharmaceuticals Inc

Alan Laboratories Inc

Alector Inc

Alectos Therapeutics

Alexza Pharmaceuticals Inc

Alkahest Inc

Alkermes Plc

Allife Medical Science and Technology Co Ltd

AlphaCognition Inc

Alsonex Pty Ltd

Alterity Therapeutics Ltd

Amathus Therapeutics Inc

Amneal Pharmaceuticals Inc

Anavex Life Sciences Corp

Annovis Bio Inc

Antoxis Ltd

Aoxing Pharmaceutical Company Inc

Apollo Therapeutics LLC

Appello Pharmaceuticals Inc

Aprinoia Therapeutics Inc

AptaBio Therapeutics Inc

Aptamer Sciences Inc

Araclon Biotech SL

Aranda Pharma Ltd

AriBio

ArmaGen Inc

Arrien Pharmaceuticals LLC

Arvinas Inc

Asdera LLC

Asklepios BioPharmaceutical Inc

Aspen Neuroscience Inc

Astellas Pharma Inc

AstraZeneca Plc

Athersys Inc

Athira Pharma Inc

Auritec Pharmaceuticals Inc

Avicanna Inc

Axial Biotherapeutics Inc

Axovant Gene Therapies Ltd

AZTherapies Inc

Azymus Therapeutics Inc

B&A Therapeutics

BCWorld Pharm Co Ltd

Belrose Pharma Inc

Berg LLC

Better Life Pharmaceuticals Inc

Bial – Portela & Ca SA

Bio-Modeling Systems SAS

Bio-Pharm Solutions Co Ltd

Bioasis Technologies Inc

Biogen Inc

Biorchestra Ltd

BlueRock Therapeutics

Bopin (Shanghai) Biomedical Technology Co Ltd

BrainEver SAS

BrainStorm Cell Therapeutics Inc

Bristol-Myers Squibb Co

C4X Discovery Holdings Plc

Calico LLC

Califia Bio Inc

Cantabio Pharmaceuticals Inc

Canvax Biotech SL

Capo Therapeutics Inc

Carmot Therapeutics Inc

Carna Biosciences Inc

Casma Therapeutics Inc

Cavion LLC

CavoGene LifeSciences

Celavie Biosciences LLC

CellCure

Cellivery Therapeutics Inc

Cellix Bio Pvt Ltd

Cerecin Inc

Cerecor Inc

CereSpir Inc

Cerevance Inc

Cerevel Therapeutics LLC

CHA Biotech Co Ltd

Chamishi Therapeutics Inc

Chase Therapeutics Corp

Chiesi Farmaceutici SpA

CholesteniX Ltd

Chongqing Pharmaceutical Research Institute Co Ltd

Ci Therapeutics

Clayton Biotechnologies Inc

Clene Nanomedicine Inc

Clevexel Pharma SA

Clexio Biosciences Ltd

Cogentis Therapeutics Inc

Collaborative Medicinal Development LLC

Contera Pharma ApS

Copernicus Therapeutics Inc

Corium Inc

Table of Contents

Table of Contents

Introduction

Parkinson's Disease - Overview

Parkinson's Disease - Therapeutics Development

Parkinson's Disease - Therapeutics Assessment

Parkinson's Disease - Companies Involved in Therapeutics Development

Parkinson's Disease - Drug Profiles

Parkinson's Disease - Dormant Projects

Parkinson's Disease - Discontinued Products

Parkinson's Disease - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Parkinson's Disease, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Parkinson's Disease – Pipeline by 1st Bio Therapeutics Inc, H2 2020

Parkinson's Disease – Pipeline by 4D Pharma Plc, H2 2020

Parkinson's Disease – Pipeline by Abaxy Sprl, H2 2020

Parkinson's Disease – Pipeline by AbbVie Inc, H2 2020

Parkinson's Disease – Pipeline by Abfero Pharmaceuticals Inc, H2 2020

Parkinson's Disease – Pipeline by Abivax SA, H2 2020

Parkinson's Disease – Pipeline by ABL Bio Inc, H2 2020

Parkinson's Disease – Pipeline by AC Immune SA, H2 2020

Parkinson's Disease – Pipeline by Accure Therapeutics SL, H2 2020

Parkinson's Disease – Pipeline by Acelot Inc, H2 2020

Parkinson's Disease – Pipeline by Addex Therapeutics Ltd, H2 2020

Parkinson's Disease – Pipeline by Adicet Bio Inc, H2 2020

Parkinson's Disease – Pipeline by Affichem SA, H2 2020

Parkinson's Disease – Pipeline by AFFiRiS AG, H2 2020

Parkinson's Disease – Pipeline by Carmot Therapeutics Inc, H2 2020

Parkinson's Disease – Pipeline by Carna Biosciences Inc, H2 2020

Parkinson's Disease – Pipeline by Casma Therapeutics Inc, H2 2020

Parkinson's Disease – Pipeline by Cavion LLC, H2 2020

Parkinson's Disease – Pipeline by CavoGene LifeSciences, H2 2020

Parkinson's Disease – Pipeline by Celavie Biosciences LLC, H2 2020

Parkinson's Disease – Pipeline by CellCure, H2 2020

Parkinson's Disease – Pipeline by Cellivery Therapeutics Inc, H2 2020

Parkinson's Disease – Pipeline by Cellix Bio Pvt Ltd, H2 2020

Parkinson's Disease – Pipeline by Cerecin Inc, H2 2020

Parkinson's Disease – Pipeline by Cerecor Inc, H2 2020

Parkinson's Disease – Pipeline by CereSpir Inc, H2 2020

Parkinson's Disease – Pipeline by Cerevance Inc, H2 2020

Parkinson's Disease – Pipeline by Cerevel Therapeutics LLC, H2 2020

Parkinson's Disease – Pipeline by CHA Biotech Co Ltd, H2 2020

Parkinson's Disease – Pipeline by Chamishi Therapeutics Inc, H2 2020

Parkinson's Disease – Pipeline by Chase Therapeutics Corp, H2 2020

Parkinson's Disease – Pipeline by Chiesi Farmaceutici SpA, H2 2020

Parkinson's Disease – Pipeline by CholesteniX Ltd, H2 2020

Parkinson's Disease – Pipeline by Chongqing Pharmaceutical Research Institute Co Ltd, H2 2020

Parkinson's Disease – Pipeline by Ci Therapeutics, H2 2020

Parkinson's Disease – Pipeline by Clayton Biotechnologies Inc, H2 2020

Parkinson's Disease – Pipeline by Clene Nanomedicine Inc, H2 2020

Parkinson's Disease – Pipeline by Clevexel Pharma SA, H2 2020

Parkinson's Disease – Pipeline by InnoMedica Holding AG, H2 2020

Parkinson's Disease – Pipeline by Intec Pharma Ltd, H2 2020

Parkinson's Disease – Pipeline by International Stem Cell Corp, H2 2020

Parkinson's Disease – Pipeline by Intra-Cellular Therapies Inc, H2 2020

Parkinson's Disease – Pipeline by Invisio Ltd, H2 2020

Parkinson's Disease – Pipeline by Io Therapeutics Inc, H2 2020

Parkinson's Disease – Pipeline by Ionis Pharmaceuticals Inc, H2 2020

Parkinson's Disease – Pipeline by IRLAB Therapeutics AB, H2 2020

Parkinson's Disease – Pipeline by Jazz Pharmaceuticals Plc, H2 2020

Parkinson's Disease – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2020

Parkinson's Disease – Pipeline by Junaxo Inc, H2 2020

Parkinson's Disease – Pipeline by Kainos Medicine Inc, H2 2020

Parkinson's Disease – Pipeline by Kariya Pharmaceuticals IVS, H2 2020

Parkinson's Disease – Dormant Projects, H2 2020

Parkinson's Disease – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Parkinson's Disease, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports